ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

目前这项研究的总体目标是解决 外源性女性激素对患者疾病活动性和严重程度的影响 系统性红斑狼疮(SLE)，一种在很大程度上影响 少数族裔女性。口服避孕药和雌激素替代药物是 一般没有规定，因为人们普遍认为他们可以 激活SLE。然而，这一普遍接受的做法只是基于 论女性占优势，雌激素的生物异常 新陈代谢，狼疮小鼠模型，患者的几件轶事 在接受外源性激素的同时出现疾病发作，以及一次回顾 对既有肾脏疾病患者的研究。相比之下，更多的 最近的回顾研究表明，耀斑的速度并不是 在服用口服避孕药的患者中，这一比例在统计上有所增加。这个 先前存在的数据不足以证明解雇 在一种疾病中潜在重要的节育选择 主要影响育龄妇女，其 这种疾病对生育能力没有明显的影响。此外，还使用了 在服用合成雌激素的患者中保持生育能力 环磷酰胺和雌激素的使用预防绝经后和 激素性骨质疏松症是及时考虑的。

The overall goal of the current study is to address the effect of exogenous female hormones on disease activity and severity in patients with systemic lupus erythematosus (SLE), a disease which largely affects minority women. Oral contraceptives and estrogen replacement are generally not prescribed due to the widely held view that they can activate SLE. However, this generally accepted practice is based only on the predominance of female gender, biologic abnormalities of estrogen metabolism, murine models of lupus, several anecdotes of patients having disease flares while receiving exogenous hormones, and one retrospective study in patients with pre-existing renal disease. In contrast, a more recent retrospective study suggests that the rate of flare is not statistically increased in patients taking oral contraceptives. The pre-existing data are insufficient to warrant the dismissal of a potentially important birth control option in a disease which predominantly affects women in their reproductive years and whose fertility is not appreciably altered by the disease. Moreover, the use of synthetic estrogens to preserve fertility in patients taking cyclophosphamide and the use of estrogens to prevent post-menopausal and steroid induced osteoporosis are timely considerations.